Corbus Pharmaceuticals Holdings, Inc. filings document a clinical-stage biotechnology issuer focused on oncology and obesity. The record includes Form 8-K material-event reports for clinical and regulatory disclosures involving CRB-701 and CRB-913, Regulation FD corporate presentations and risk language tied to product development, trial timelines and business strategy.
Proxy and governance filings cover board matters, executive compensation, equity awards, employment agreements and officer or director changes. The filings also provide formal disclosure categories for operating and financial results and the governance framework supporting the company’s drug-development pipeline.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported that Aberdeen Group plc and its U.S. affiliate abrdn Inc. have become significant shareholders. The filing shows that these related entities beneficially own a total of 1,321,750 shares of Corbus common stock, representing 7.53% of the outstanding shares as of the reported date. Both Aberdeen Group plc (United Kingdom) and abrdn Inc. (United States) report shared voting and dispositive power over all of these shares, with no sole voting or sole dispositive authority.
The securities are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Corbus, consistent with an institutional investment position under Schedule 13G. The filing notes that abrdn Inc. holds more than 5% of this class of stock on behalf of its underlying clients, with Aberdeen Group plc as the parent company and abrdn Holdings Limited as an intermediate holding company.
Corbus Pharmaceuticals Holdings, Inc. filed a current report to let investors know that management has updated the company’s investor presentation. The revised presentation is being used to describe its business and is furnished as Exhibit 99.1 to the report. The company notes that this material is being provided under a Regulation FD disclosure item, meaning it is intended to share information broadly with the market. The investor presentation and related materials are furnished rather than filed, so they are not automatically subject to certain liability provisions or incorporated into other securities filings unless specifically referenced.
Corbus Pharmaceuticals Holdings, Inc. announced that long-time board member Alan Holmer has decided to retire from its Board of Directors. He notified the company of his resignation on December 12, 2025, and his service will end effective December 31, 2025. The company states that his decision to step down is due to retirement and is not the result of any disagreement with management or with the company’s operations, policies, or practices. This indicates an orderly governance transition rather than a conflict-driven departure.
Corbus Pharmaceuticals Holdings, Inc. insiders affiliated with Cormorant Asset Management reported selling 30,029 shares of common stock on 12/11/2025. The sale was coded as a disposition and executed in a series of open-market transactions at a weighted average price of $11.456 per share, with individual trade prices ranging from $11.20 to $12.15.
Following this transaction, the reporting persons indirectly beneficially owned 2,344,971 Corbus Pharmaceuticals shares. The filing states that all shares sold were held by Cormorant Global Healthcare Master Fund, LP and that each reporting person disclaims beneficial ownership beyond its or her pecuniary interest.
Corbus Pharmaceuticals (CRBP) reported Q3 2025 results, highlighting higher R&D spending as clinical programs advanced. The company posted a net loss of $23.3 million versus $13.8 million a year ago, driven by R&D of $20.9 million (up 93%) as CRB-701 and CRB-601 trials expanded and CRB-913 progressed in Phase 1. G&A declined to $3.6 million from $4.7 million.
Liquidity remained solid. Cash, cash equivalents and investments were $104.0 million as of September 30, 2025. Management stated that these resources, together with $73.8 million in net proceeds from recent equity sales and the 2025 public offering, are expected to fund operations for at least twelve months after this report’s issuance. Net cash used in operations was $48.6 million for the nine months.
Subsequent to quarter-end, the company sold 232,279 shares via its Open Market Sale Agreement for net proceeds of $3.6 million and completed a public offering on November 3, 2025, raising gross proceeds of $75.0 million (net $70.2 million). Shares outstanding were 12,534,853 as of September 30, 2025.
Corbus Pharmaceuticals Holdings, Inc. filed a current report describing that it issued a press release on November 12, 2025 with financial information and operating metrics for its fiscal quarter ended September 30, 2025, along with a discussion of its business outlook. The press release is attached as Exhibit 99.1 and is incorporated by reference.
The company notes that the information provided under Items 2.02 and 7.01, including Exhibit 99.1, is being furnished to the SEC and is not deemed filed for liability purposes under the Exchange Act or automatically incorporated into other securities filings, unless specifically referenced.
Corbus Pharmaceuticals (CRBP) entered an underwriting agreement for a public offering of 4,744,231 shares of common stock at $13.00 per share and pre-funded warrants to purchase up to 1,025,000 shares at $12.9999 per warrant. Underwriters also received a 30‑day option to buy up to 865,384 additional shares at the public price.
Corbus expects approximately $70.5 million in net proceeds from the transaction, which is being conducted under an effective Form S‑3 shelf registration. The closing is expected on or about November 3, 2025, subject to customary conditions. The pre-funded warrants are exercisable at any time after issuance, with a 9.99% beneficial ownership cap that holders can adjust up to 19.99% with notice, effective on the 61st day.
The offering terms were described in a final prospectus supplement dated October 30, 2025. The company noted customary representations, indemnities, and termination provisions in the underwriting agreement.
Corbus Pharmaceuticals (CRBP) launched a public offering of 4,744,231 shares at $13.00 per share and 1,025,000 pre-funded warrants, together with 1,025,000 shares issuable upon warrant exercise. The company expects $70.5 million in proceeds before expenses and estimates approximately $70.2 million in net proceeds. Underwriters have a 30‑day option to buy up to 865,384 additional shares.
The pre-funded warrants are immediately exercisable at $0.0001 per share. Shares outstanding will be 18,528,517 after the offering (or 19,393,901 if the option is fully exercised), assuming full exercise of pre-funded warrants. Corbus plans to use proceeds to fund clinical development across its pipeline and for working capital and general corporate purposes.
As context, Corbus reported $104.0 million in cash, cash equivalents, and investments as of September 30, 2025, and has sold 505,217 shares via its ATM since June 30, 2025 for $6.7 million in gross proceeds. The filing’s dilution analysis indicates an immediate dilution of $2.96 per share to new investors at the offering price.
Corbus Pharmaceuticals (CRBP) provided a preliminary financial update for the quarter ended September 30, 2025. Management estimates cash, cash equivalents, and investments of approximately $104.0 million as of September 30, 2025, including $27.0 million in cash and cash equivalents.
These figures are preliminary and unaudited, subject to normal closing procedures and potential adjustments. The company’s independent registered public accounting firm has not audited, reviewed, or compiled this data and offers no assurance. The estimate does not reflect any activity after September 30, 2025, including sales under the company’s Open Market Sale Agreement with Jefferies LLC, as amended. Corbus notes the estimate may change when final results are filed.
Corbus Pharmaceuticals (CRBP) launched a preliminary prospectus supplement for a primary offering of common stock and, at investors’ election, pre‑funded warrants, with the underwriters granted a 30‑day option to purchase additional shares. The pre‑funded warrants are immediately exercisable for one share at an exercise price of $0.0001 per share and include a 9.99% Beneficial Ownership Limitation (electable up to 19.99% with notice).
The company plans to use net proceeds to fund clinical development across its oncology and obesity programs and for working capital and general corporate purposes. As context, the stock last closed at $16.86 on October 29, 2025, and Corbus preliminarily estimates cash, cash equivalents, and investments of approximately $104.0 million as of September 30, 2025. Since June 30, 2025, it sold 505,217 shares via its at‑the‑market program for $6.7 million. Shares outstanding were 12,254,069 as of June 30, 2025, after giving effect to those ATM sales.